Who
R. Scott Greer
Director
Company insider
Files Form 4 as: Director, Nektar Therapeutics; Director, Inogen; Director, Sientra; Director, Versartis; Director, Microbot Medical; Director, Auspex Pharmaceuticals; Director, Sirna Therapeutics; Director, Abgenix.
In numbers
- Trades disclosed
- 139
- Buys
- 5
- Sells
- 5
- Bought
- $649K
- Sold
- $4.4M
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 1 Apr 2006
- Last trade
- 23 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 30 Sep 2025filed 1 Oct 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 18 Sep 2024filed 17 Jan 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 19 Sep 2023filed 21 Sep 2023 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 16 Sep 2022filed 20 Sep 2022 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 16 Sep 2022filed 20 Sep 2022 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,200 at $0.00 | filing |
| 9 Nov 2021filed 9 Nov 2021 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 9 Nov 2021filed 9 Nov 2021 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code M | $160K12,500 at $12.80 | filing |
| 22 Sep 2021filed 24 Sep 2021 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 22 Sep 2021filed 24 Sep 2021 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,200 at $0.00 | filing |
| 31 Aug 2021filed 31 Aug 2021 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —45,000 at $0.00 | filing |
| 31 Aug 2021filed 31 Aug 2021 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code M | $572K45,000 at $12.70 | filing |
| 10 May 2021filed 12 May 2021 | INGN InogenMedical Devices | SEC FORM 4 Code A | —2,754 at $0.00 | filing |
| 3 Feb 2021filed 4 Feb 2021 | INGN Inogenoption or derivative · Medical Devices | SEC FORM 4 Code M | —6,666 at $0.00 | filing |
| 3 Feb 2021filed 4 Feb 2021 | INGN Inogenoption or derivative · Medical Devices | SEC FORM 4 Code M | —3,334 at $0.00 | filing |
| 3 Feb 2021filed 4 Feb 2021 | INGN Inogenoption or derivative · Medical Devices | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 3 Feb 2021filed 4 Feb 2021 | INGN InogenMedical Devices | SEC FORM 4 Code M | $311K6,666 at $46.66 | filing |
News
Nektar Therapeutics (NASDAQ:NKTR) Research Coverage Started at Leerink PartnersNKTR · tickerreport.com · 15 Oct 2026Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink PartnersNKTR · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name R. Scott Greer; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.